-
Je něco špatně v tomto záznamu ?
Oral versus intravenous ibuprofen for the early closure of patent ductus arteriosus in low birth weight preterm infants
Alketa Hoxha, Ermira Kola, Numila Kuneshka, Eduard Tushe
Jazyk angličtina Země Česko Médium elektronický zdroj
Digitální knihovna NLK
Plný text - Článek
Číslo
Ročník
Zdroj
Zdroj
NLK
ROAD: Directory of Open Access Scholarly Resources
od 2011 do 2017
- MeSH
- aplikace orální * MeSH
- barevná dopplerovská echokardiografie MeSH
- dusík močoviny v krvi MeSH
- gestační stáří MeSH
- ibuprofen * aplikace a dávkování škodlivé účinky MeSH
- intravenózní podání * statistika a číselné údaje MeSH
- kreatinin krev MeSH
- lidé MeSH
- nemoci nedonošenců farmakoterapie MeSH
- novorozenec nedonošený MeSH
- novorozenec s nízkou porodní hmotností * MeSH
- novorozenec MeSH
- oligurie chemicky indukované MeSH
- otevřená tepenná dučej * farmakoterapie MeSH
- porodní hmotnost MeSH
- prospektivní studie MeSH
- statistika jako téma MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- ženské pohlaví MeSH
Background Patent ductus arteriosus (PDA) is common in very premature infants. Pharmacological closure of PDA with indomethacin, a prostaglandin inhibitor, has remained the mainstay of treatment in premature infants over the last three decades. Intravenous ibuprofen was recently shown to be as effective and to have fewer adverse reaction in preterm infants. If equally effective, then oral ibuprofen for PDA closure would have several important advantages over the intravenous route. This study was designed to assess the efficacy and safety of oral ibuprofen and intravenous ibuprofen for the early pharmacological treatment of PDA in LBW preterm infants with respiratory distress syndrome. Methods A randomized, single-blinded, controlled study was performed on premature neonates at the neonatal care unit of the University Hospital for Obstetrics and Gynecology”Koco Gliozheni”, Tirana, Albania, from January 2010 to December 2012. The study enrolled 68 preterm infants with gestational age between 28-32 weeks, birth weight ≤ 2000 g, postnatal age 48-96 h, and had echocardiographically confirmed significant PDA. The preterm infants received either intravenous or oral ibuprofen randomly as an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h. After the first dose of treatment in both groups, echocardiographic evaluation was performed, to determine the need for a second or third dose. The rate of ductal closure, adverse effects, complications, and the patient’s clinical course were recorded. Results All patients were born after 28 until 32 weeks’ gestation. 36 patients were treated with oral ibuprofen and 32 with intravenous ibuprofen in this period. After the first course of the treatment, the PDA closed in 30 (83.3%) of the patients assigned to the oral ibuprofen group versus 23 (71.8%) of those enrolled in the intravenous ibuprofen group (p = 0.355). There was no difference between treatment groups in demographics or baseline renal function. In the evaluation of renal tolerance, none of the patients had oliguria. There were no significant differences with respect to complications during the stay. Conclusions In low birth weight infants, the rate of early ductal closure with oral ibuprofen is at least as good as with the intravenous route. Oral ibuprofen is associated with fewer adverse effects
Oral versus intravenous ibuprofen for the early closure of patent ductus arteriosus in low birth weight preterm infants [elektronický zdroj] /
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14060603
- 003
- CZ-PrNML
- 005
- 20140807111738.0
- 007
- cr|cn|
- 008
- 140606s2013 xr d fs 000 0eng||
- 009
- eAR
- 024 7_
- $a 10.12955/emhpj.v6i0.388 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Hoxha, Alketa $u University Hospital for Obstetrics and Gynecology, Tirana, Albania
- 245 10
- $a Oral versus intravenous ibuprofen for the early closure of patent ductus arteriosus in low birth weight preterm infants $h [elektronický zdroj] / $c Alketa Hoxha, Ermira Kola, Numila Kuneshka, Eduard Tushe
- 504 __
- $a Literatura
- 520 9_
- $a Background Patent ductus arteriosus (PDA) is common in very premature infants. Pharmacological closure of PDA with indomethacin, a prostaglandin inhibitor, has remained the mainstay of treatment in premature infants over the last three decades. Intravenous ibuprofen was recently shown to be as effective and to have fewer adverse reaction in preterm infants. If equally effective, then oral ibuprofen for PDA closure would have several important advantages over the intravenous route. This study was designed to assess the efficacy and safety of oral ibuprofen and intravenous ibuprofen for the early pharmacological treatment of PDA in LBW preterm infants with respiratory distress syndrome. Methods A randomized, single-blinded, controlled study was performed on premature neonates at the neonatal care unit of the University Hospital for Obstetrics and Gynecology”Koco Gliozheni”, Tirana, Albania, from January 2010 to December 2012. The study enrolled 68 preterm infants with gestational age between 28-32 weeks, birth weight ≤ 2000 g, postnatal age 48-96 h, and had echocardiographically confirmed significant PDA. The preterm infants received either intravenous or oral ibuprofen randomly as an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h. After the first dose of treatment in both groups, echocardiographic evaluation was performed, to determine the need for a second or third dose. The rate of ductal closure, adverse effects, complications, and the patient’s clinical course were recorded. Results All patients were born after 28 until 32 weeks’ gestation. 36 patients were treated with oral ibuprofen and 32 with intravenous ibuprofen in this period. After the first course of the treatment, the PDA closed in 30 (83.3%) of the patients assigned to the oral ibuprofen group versus 23 (71.8%) of those enrolled in the intravenous ibuprofen group (p = 0.355). There was no difference between treatment groups in demographics or baseline renal function. In the evaluation of renal tolerance, none of the patients had oliguria. There were no significant differences with respect to complications during the stay. Conclusions In low birth weight infants, the rate of early ductal closure with oral ibuprofen is at least as good as with the intravenous route. Oral ibuprofen is associated with fewer adverse effects
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a novorozenec nedonošený $7 D007234
- 650 12
- $a novorozenec s nízkou porodní hmotností $7 D007230
- 650 _2
- $a nemoci nedonošenců $x farmakoterapie $7 D007235
- 650 12
- $a otevřená tepenná dučej $x farmakoterapie $7 D004374
- 650 12
- $a ibuprofen $x aplikace a dávkování $x škodlivé účinky $7 D007052
- 650 12
- $a aplikace orální $7 D000284
- 650 12
- $a intravenózní podání $x statistika a číselné údaje $7 D061605
- 650 _2
- $a gestační stáří $7 D005865
- 650 _2
- $a porodní hmotnost $7 D001724
- 650 _2
- $a barevná dopplerovská echokardiografie $7 D018618
- 650 _2
- $a oligurie $x chemicky indukované $7 D009846
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a statistika jako téma $7 D013223
- 650 _2
- $a kreatinin $x krev $7 D003404
- 650 _2
- $a dusík močoviny v krvi $7 D001806
- 700 1_
- $a Kola, Ermira $u University Hospital for Obstetrics and Gynecology, Tirana, Albania
- 700 1_
- $a Kuneshka, Numila $u University Hospital for Obstetrics and Gynecology, Tirana, Albania
- 700 1_
- $a Tushe, Eduard $u University Hospital for Obstetrics and Gynecology, Tirana, Albania
- 773 0_
- $t European medical, health and pharmaceutical journal $x 1804-5804 $g Roč. 2013, č. 6 (2013), s. 14-19 $w MED00177703
- 856 41
- $u https://ojs.journals.cz/index.php/EMHPJ/issue/view/47 $y plný text volně přístupný
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20140606091057 $b ABA008
- 991 __
- $a 20140807112051 $b ABA008
- 999 __
- $a ok $b bmc $g 1027824 $s 859253
- BAS __
- $a 3 $a 4 $a PRD
- BMC __
- $a 2013 $b 2013 $c 6 $d 14-19 $i 1804-5804 $m European Medical, Health and Pharmaceutical Journal $n Eur. Med. Health Pharm. J. $x MED00177703
- LZP __
- $c NLK188 $d 20140807 $a NLK 2014-09/pk